SLC2A1-4 is upregulated in multiple cancer types (e.g., pancreatic, lung, and prostate), so there is significant interest in developing therapeutics targeting these transporters (Adekola et al., 2012; Holman, 2020; Pliszka and Szablewski, 2021). This evidence concerns the gene SLC2A1 and cancer.